Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
| Descriptor ID |
D020277
|
| MeSH Number(s) |
C10.114.750.175 C10.314.750.700 C10.668.829.800.750.600 C20.111.258.750.800
|
| Concept/Terms |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- CIDP
- Polyneuropathy, Inflammatory Demyelinating, Chronic
- Inflammatory Polyradiculopathy, Chronic
- Chronic Inflammatory Polyradiculopathies
- Chronic Inflammatory Polyradiculopathy
- Inflammatory Polyradiculopathies, Chronic
- Polyradiculopathies, Chronic Inflammatory
- Polyradiculopathy, Chronic Inflammatory
- Polyradiculoneuropathy, Chronic Inflammatory
- Chronic Inflammatory Polyradiculoneuropathy
- Chronic Inflammatory Polyradiculoneuropathies
- Polyradiculoneuropathies, Chronic Inflammatory
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
Below are MeSH descriptors whose meaning is more general than "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating".
Below are MeSH descriptors whose meaning is more specific than "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating".
This graph shows the total number of publications written about "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" by people in this website by year, and whether "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2017 | 7 | 0 | 7 |
| 2018 | 6 | 0 | 6 |
| 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating" by people in Profiles.
-
Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst. 2021 06; 26(2):148-154.
-
COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy. J Neurol. 2021 Sep; 268(9):3129-3131.
-
Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy. Neurol Sci. 2021 Mar; 42(3):787-789.
-
Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. J Neurol Sci. 2020 11 15; 418:117106.
-
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e590.
-
FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis. J Neuroinflammation. 2019 Mar 02; 16(1):54.
-
Immune-mediated neuropathies. Nat Rev Dis Primers. 2018 10 11; 4(1):31.
-
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018 08; 17(8):689-698.
-
An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies. J Autoimmun. 2018 08; 92:114-125.
-
Intravenous versus subcutaneous immunoglobulin. Lancet Neurol. 2018 05; 17(5):393.